Cytomegalovirus antivirals and development of improved animal models

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 10, 2011, Pages 1245-1265

  McGregor, Alistair ^a   Choi, K Yeon ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antiviral; Bioluminescence imaging; CMV; Congenital infection; Drug resistance; Drug toxicity; Ganciclovir; Guinea pig; Humanized virus; Maribavir; Mouse; UL54; UL89; UL97

Indexed keywords

2 BROMO 5,6 DICHLORO 1 BETA D RIBOFURANOSYL; 2' DEOXY 4 THIOPYRIMIDINE NUCLEOSIDE; 3,4 DIHYDRO QUINAZOLINE 4 YL ACETIC; 5 IODO 4' THIO 2' DEOXYURIDINE; ACICLOVIR; AIC 246; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; CYCLOPROPAVIR; EVEROLIMUS; FOSCARNET SODIUM; GANCICLOVIR; GW 275175 X; HYPERIMMUNE GLOBULIN; INDOLOCARBOZOLE; LEFLUNOMIDE; RAPAMYCIN; TOMEGLOVIR; UNCLASSIFIED DRUG; VALACICLOVIR; VALCYCLOPROPAVIR; VALGANCICLOVIR; VIRUS DNA;

ANEMIA; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; DNA REPLICATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL DISEASE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; NEUTROPENIA; NONHUMAN; PHLEBITIS; REVIEW; RNA INTERFERENCE; THROMBOCYTOPENIA; VIRUS MORPHOLOGY;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HUMANS; MODELS, ANIMAL;

ANIMALIA; CAVIA; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 80053032920     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.613824     Document Type: Review

References (199)

1. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005;49(3):873-83 (Pubitemid 40327699)
2. Ross SA, Boppana SB. Congenital cytomegalovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis 2005;16(1):44-9 (Pubitemid 40430829)
3. Griffiths PD, Walter S. Cytomegalovirus. Curr Opin Infect Dis 2005;18(3):241-5 (Pubitemid 40769182)
4. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007;17(4):253-76 (Pubitemid 47066638)
5. Colugnati FA, Staras SA, Dollard SC, et al. Incidence of cytomegalovirus infection among the general population and pregnant women in the united states. BMC Infect Dis 2007;7:71
6. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003;289(8):1008-11 (Pubitemid 37432932)
7. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007;17(5):355-63 (Pubitemid 47425872)
8. Pass RF. Immunization strategy for prevention of congenital cytomegalovirus infection. Infect Agents Dis 1996;5(4):240-4 (Pubitemid 26317987)
9. Caposio P, Orloff SL, Streblow DN. The role of cytomegalovirus in angiogenesis. Virus Res 2011;157(2):204-11
10. Streblow DN, Dumortier J, Moses AV, et al. Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol 2008;325:397-415
11. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res 2011;157(2):193-203
12. Hahn G, Revello MG, Patrone M, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004;78(18):10023-33 (Pubitemid 39187120)
13. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 2005a;102(50):18153-8 (Pubitemid 41798517)
14. Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005b;79(16):10330-8 (Pubitemid 41098573)
15. Ryckman BJ, Jarvis MA, Drummond DD, et al. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 2006;80(2):710-22 (Pubitemid 43062884)
16. Patrone M, Secchi M, Fiorina L, et al. Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 2005;79(13):8361-73 (Pubitemid 40853539)
17. Simanek AM, Dowd JB, Pawelec G, et al. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the united states. PLoS One 2011;6(2):e16103
18. Strandberg TE, Pitkala KH, Tilvis RS. Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease. JAMA 2009;301(4):380-2
19. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 2010;9(11):1303-14
20. Dolan A, Cunningham C, Hector RD, et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol 2004;85(Pt 5):1301-12 (Pubitemid 38659794)
21. Mocarski ES, Courcelle CT. Cytomegalovirus and their replication. In: Knipe DM, Howley PM. editors. Fields virology. 4th edition. Lippincott Williams and Wilkins; Philadelphia, PA: 2001. p. 2629-73
22. Dargan DJ, Douglas E, Cunningham C, et al. Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol 2010;91(Pt 6):1535-46
23. Macagno A, Bernasconi NL, Vanzetta F, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/ gL/UL128-131A complex. J Virol 2010;84(2):1005-13
24. Saccoccio FM, Sauer AL, Cui X, et al. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 2011;29(15):2705-11
25. Razonable RR, Emery VC. 11th Annual Meeting of the IHMF (International Herpes Management Forum). Management of CMV infection and disease in transplant patients. Herpes 2004;11(3):77-86
26. Sullivan V, Talarico CL, Stanat SC, et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358(6382):162-4
27. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010;23(4):689-712
28. Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002;185(2):162-9 (Pubitemid 34056439)
29. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008;18(4):233-46 (Pubitemid 352018847)
30. Baldanti F, Michel D, Simoncini L, et al. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res 2002;54(1):59-67 (Pubitemid 34219175)
31. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143(1):16-25 (Pubitemid 36928564)
32. Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National institute of allergy and infectious diseases collaborative antiviral study group. J Infect Dis 1997;175(5):1080-6 (Pubitemid 27176494)
33. Bradford RD, Cloud G, Lakeman AD, et al. Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J Infect Dis 2005;191(2):227-33 (Pubitemid 40096380)
34. Oliver SE, Cloud GA, Sanchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 2009;46(Suppl 4):S22-6
35. Kimberlin DW. Antiviral therapy for cytomegalovirus infections in pediatric patients. Semin Pediatr Infect Dis 2002;13(1):22-30 (Pubitemid 34171342)
36. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994;10(4):281-91 (Pubitemid 24126220)
37. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39(4):597-638
38. Sharland M, Luck S, Griffiths P, et al. Antiviral therapy of CMV disease in children. Adv Exp Med Biol 2011;697:243-60
39. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99(4):1159-64 (Pubitemid 34547067)
40. Mattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004;189(8):1355-61 (Pubitemid 38543583)
41. Luck S, Sharland M, Griffiths P, et al. Advances in the antiviral therapy of herpes virus infection in children. Expert Rev Anti Infect Ther 2006;4(6):1005-20 (Pubitemid 46040352)
42. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994;48(2):199-226 (Pubitemid 24260355)
43. Smith IL, Cherrington JM, Jiles RE, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997;176(1):69-77 (Pubitemid 27272853)
44. Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998;72(7):5927-36 (Pubitemid 28283381)
45. Chou S, Lurain NS, Thompson KD, et al. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003;188(1):32-9 (Pubitemid 36829739)
46. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006;71(2-3):154-63 (Pubitemid 44223768)
47. Bischofberger N, Hitchcock MJ, Chen MS, et al. 1- [((S)-2-hydroxy-2- oxo-1,4,2-dioxaphosphorinan-5-yl) methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994;38(10):2387-91 (Pubitemid 24304235)
48. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002;55(1):1-13 (Pubitemid 34655638)
49. Bravo FJ, Stanberry LR, Kier AB, et al. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. Antiviral Res 1993;21(1):59-72 (Pubitemid 23119402)
50. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002;46(8):2381-6 (Pubitemid 34793439)
51. Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003;59(3):163-71 (Pubitemid 36966748)
52. Kern ER, Collins DJ, Wan WB, et al. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48(9):3516-22 (Pubitemid 39129353)
53. Bravo FJ, Bernstein DI, Beadle JR, et al. Oral hexadecyloxypropyl- cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. Antimicrob Agents Chemother 2011;55(1):35-41
54. Williams-Aziz SL, Hartline CB, Harden EA, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 2005;49(9):3724-33 (Pubitemid 41233024)
55. Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005;191(3):396-9 (Pubitemid 40139765)
56. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009;82(2):A84-98
57. Eriksson U, Peterson LW, Kashemirov BA, et al. Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. Mol Pharm 2008;5(4):598-609
58. Tehler U, Nelson CH, Peterson LW, et al. Puromycin-sensitive aminopeptidase: An antiviral prodrug activating enzyme. Antiviral Res 2010;85(3):482-9
59. Peterson LW, Kim JS, Kijek P, et al. Synthesis, transport and antiviral activity of ala-ser and val-ser prodrugs of cidofovir. Bioorg Med Chem Lett 2011;21(13):4045-9
60. Kern ER, Kushner NL, Hartline CB, et al. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother 2005;49(3):1039-45 (Pubitemid 40327721)
61. Wu Z, Drach JC, Prichard MN, et al. L-valine ester of cyclopropavir: a new antiviral prodrug. Antivir Chem Chemother 2009;20(1):37-46
62. Borysko KZ, Gentry BG, Breitenbach JM, et al. Resistacne of human cytomegalovirus to cyclopropavir involves a novel mutation in UL97. Antiviral Res 2008;78:A54
63. Tucker JA, Clayton TL, Chidester CG, et al. Structure-activity relationships of acyloxyamidine cytomegalovirus DNA polymerase inhibitors. Bioorg Med Chem 2000;8(3):601-15 (Pubitemid 30122367)
64. Vaillancourt VA, Cudahy MM, Staley SA, et al. Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase. Bioorg Med Chem Lett 2000;10(18):2079-81
65. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002;46(8):2365-72 (Pubitemid 34793437)
66. Krosky PM, Baek MC, Jahng WJ, et al. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol 2003;77(14):7720-7 (Pubitemid 36792768)
67. Marschall M, Freitag M, Suchy P, et al. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 2003;311(1):60-71 (Pubitemid 36794210)
68. Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 2009;19(4):215-29
69. Komazin G, Ptak RG, Emmer BT, et al. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol 2003;77(21):11499-506 (Pubitemid 37271648)
70. Chou S, Marousek GI, Senters AE, et al. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 2004;78(13):7124-30 (Pubitemid 38781550)
71. Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob Agents Chemother 2009;53(1):81-5
72. Drew WL, Miner RC, Marousek GI, et al. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006;37(2):124-7 (Pubitemid 44441975)
73. Wang LH, Peck RW, Yin Y, et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003;47(4):1334-42 (Pubitemid 36368594)
74. Chou S, Marousek GI. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 2006;50(10):3470-2 (Pubitemid 44527529)
75. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111(11):5403-10
76. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011;11(4):284-92
77. Uknis M. In: Prophylaxis against CMV with oral MBV in allogeneic stem cell transplant recipients: results of a randomized double blind placebo controlled trial. 12th international CMV/ Betaherpesvirus workshop; Boston; 2009
78. Marschall M, Stein-Gerlach M, Freitag M, et al. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J Gen Virol 2002;83(Pt 5):1013-23 (Pubitemid 34477273)
79. Herget T, Freitag M, Morbitzer M, et al. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob Agents Chemother 2004;48(11):4154-62 (Pubitemid 39434869)
80. Zimmermann A, Wilts H, Lenhardt M, et al. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res 2000;48(1):49-60
81. Bras AP, Sitar DS, Aoki FY. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Can J Clin Pharmacol 2001;8(4):207-11 (Pubitemid 34072386)
82. Evers DL, Komazin G, Ptak RG, et al. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob Agents Chemother 2004;48(10):3918-27 (Pubitemid 39304622)
83. Thoma C, Borst E, Messerle M, et al. Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus. Biochemistry 2006;45(29):8855-63 (Pubitemid 44100681)
84. Reefschlaeger J, Bender W, Hallenberger S, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 2001;48(6):757-67 (Pubitemid 33735310)
85. McSharry JJ, McDonough A, Olson B, et al. Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob Agents Chemother 2001;45(10):2925-7 (Pubitemid 32906694)
86. Underwood MR, Ferris RG, Selleseth DW, et al. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob Agents Chemother 2004;48(5):1647-51 (Pubitemid 38544370)
87. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010;54(3):1290-7
88. Hwang JS, Kregler O, Schilf R, et al. Identification of acetylated, tetrahalogenated benzimidazole D-ribonucleosides with enhanced activity against human cytomegalovirus. J Virol 2007;81(21):11604-11 (Pubitemid 47623792)
89. Hwang JS, Schilf R, Drach JC, et al. Susceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole D-ribonucleosides. Antimicrob Agents Chemother 2009;53(12):5095-101
90. De Clercq E. Nucleoside analogues exerting antiviral activity through a non-nucleoside mechanism. Nucleosides Nucleotides Nucleic Acids 2004;23(1-2):457-70 (Pubitemid 38404273)
91. Wiebusch L, Truss M, Hagemeier C. Inhibition of human cytomegalovirus replication by small interfering RNAs. J Gen Virol 2004;85(Pt 1):179-84 (Pubitemid 38128883)
92. Dunn W, Trang P, Khan U, et al. RNase P-mediated inhibition of cytomegalovirus protease expression and viral DNA encapsidation by oligonucleotide external guide sequences. Proc Natl Acad Sci USA 2001;98(26):14831-6 (Pubitemid 34013930)
93. Yang YH, Li H, Zhou T, et al. Engineered external guide sequences are highly effective in inducing RNase P for inhibition of gene expression and replication of human cytomegalovirus. Nucleic Acids Res 2006;34(2):575-83 (Pubitemid 43240245)
94. Bai Y, Trang P, Li H, et al. Effective inhibition in animals of viral pathogenesis by a ribozyme derived from RNase P catalytic RNA. Proc Natl Acad Sci USA 2008;105(31):10919-24
95. Loregian A, Rigatti R, Murphy M, et al. Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit. J Virol 2003;77(15):8336-44 (Pubitemid 36871462)
96. Loregian A, Coen DM. Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. Chem Biol 2006;13(2):191-200 (Pubitemid 43255591)
97. Gebert S, Schmolke S, Sorg G, et al. The UL84 protein of human cytomegalovirus acts as a transdominant inhibitor of immediate-early-mediated transactivation that is able to prevent viral replication. J Virol 1997;71(9):7048-60 (Pubitemid 27355371)
98. Colletti KS, Xu Y, Cei SA, et al. Human cytomegalovirus UL84 oligomerization and heterodimerization domains act as transdominant inhibitors of oriLyt-dependent DNA replication: evidence that IE2-UL84 and UL84-UL84 interactions are required for lytic DNA replication. J Virol 2004;78(17):9203-14 (Pubitemid 39096530)
99. Kaiser N, Lischka P, Wagenknecht N, et al. Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84. J Virol 2009;83(22):11902-13
100. McGregor A, Choi KY, Schleiss MR. Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV. Virology 2011;410(1):76-87
101. English EP, Chumanov RS, Gellman SH, et al. Rational development of beta-peptide inhibitors of human cytomegalovirus entry. J Biol Chem 2006;281(5):2661-7 (Pubitemid 43845728)
102. Secrist JA III, Tiwari KN, Riordan JM, et al. Synthesis and biological activity of 2-deoxy-4-thio pyrimidine nucleosides. J Med Chem 1991;34(8):2361-6
103. Nigro G, Adler SP, La Torre R, et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005;353(13):1350-62 (Pubitemid 41362703)
104. Adler SP, Nigro G. Findings and conclusions from CMV hyperimmune globulin treatment trials. J Clin Virol 2009;46(Suppl 4):S54-7
105. Cui X, McGregor A, Schleiss MR, et al. Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication. J Virol Methods 2008a;149(2):231-9
106. Gerna G, Lilleri D, Rognoni V, et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant 2009;9(5):1142-50
107. Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006;6(1):69-75 (Pubitemid 43382202)
108. Efferth T, Romero MR, Wolf DG, et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008;47(6):804-11
109. Demopoulos L, Polinsky M, Steele G, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008;40(5):1407-10 (Pubitemid 351853135)
110. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007;84(11):1436-42 (Pubitemid 350294718)
111. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: A cohort analysis. Blood 2007;110(2):490-500 (Pubitemid 47105386)
112. Hansen SG, Strelow LI, Franchi DC, et al. Complete sequence and genomic analysis of rhesus cytomegalovirus. J Virol 2003;77(12):6620-36 (Pubitemid 36666856)
113. Rawlinson WD, Farrell HE, Barrell BG. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol 1996;70(12):8833-49 (Pubitemid 26378467)
114. Schleiss MR, McGregor A, Choi KY, et al. Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome. Virol J 2008;5(1):139
115. Vink C, Beuken E, Bruggeman CA. Complete DNA sequence of the rat cytomegalovirus genome. J Virol 2000;74(16):7656-65 (Pubitemid 30613114)
116. Yamada S, Nozawa N, Katano H, et al. Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130. Virology 2009;391(1):99-106
117. Cheng TP, Valentine MC, Gao J, et al. Stability of murine cytomegalovirus genome after in vitro and in vivo passage. J Virol 2010;84(5):2623-8
118. Davison AJ, Dolan A, Akter P, et al. The human cytomegalovirus genome revisited: Comparison with the chimpanzee cytomegalovirus genome. J Gen Virol 2003;84(Pt 1):17-28 (Pubitemid 36113546)
119. Rivailler P, Kaur A, Johnson RP, et al. Genomic sequence of rhesus cytomegalovirus 180.92: Insights into the coding potential of rhesus cytomegalovirus. J Virol 2006;80(8):4179-82
120. Lilja AE, Shenk T. Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types. Proc Natl Acad Sci USA 2008;105(50):19950-5
121. Oxford KL, Eberhardt MK, Yang KW, et al. Protein coding content of the UL)b region of wild-type rhesus cytomegalovirus. Virology 2008;373(1):181-8 (Pubitemid 351384684)
122. Nozawa N, Yamamoto Y, Fukui Y, et al. Identification of a 1.6 kb genome locus of guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture. Virology 2008;379(1):45-54
123. Revello MG, Gerna G. Human cytomegalovirus tropism for endothelial/epithelial cells: Scientific background and clinical implications. Rev Med Virol 2010;20(3):136-55
124. Kern ER. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res 2006;71(2-3):164-71
125. Redwood AJ, Messerle M, Harvey NL, et al. Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception. J Virol 2005;79(5):2998-3008 (Pubitemid 40270579)
126. Smith LM, McWhorter AR, Masters LL, et al. Laboratory strains of murine cytomegalovirus are genetically similar to but phenotypically distinct from wild strains of virus. J Virol 2008;82(13):6689-96 (Pubitemid 351877063)
127. Messerle M, Crnkovic I, Hammerschmidt W, et al. Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci USA 1997;94(26):14759-63 (Pubitemid 28041447)
128. Voigt V, Forbes CA, Tonkin JN, et al. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc Natl Acad Sci USA 2003;100(23):13483-8 (Pubitemid 37444768)
129. Lee SH, Zafer A, de Repentigny Y, et al. Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice. J Exp Med 2003;197(4):515-26 (Pubitemid 36278606)
130. Bubic I, Wagner M, Krmpotic A, et al. Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 2004;78(14):7536-44 (Pubitemid 38915900)
131. Smee DF, Morris JL, Leonhardt JA, et al. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1- [3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob Agents Chemother 1992;36(9):1837-42
132. Smee DF, Sugiyama ST, Reist EJ. Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice. Antimicrob Agents Chemother 1994;38(9):2165-8 (Pubitemid 24278819)
133. Bidanset DJ, Rybak RJ, Hartline CB, et al. Replication of human cytomegalovirus in severe combined immunodeficient mice implanted with human retinal tissue. J Infect Dis 2001;184(2):192-5 (Pubitemid 32614049)
134. DiLoreto D Jr, Epstein LG, Lazar ES, et al. Cytomegalovirus infection of human retinal tissue: An in vivo model. Lab Invest 1994;71(1):141-8 (Pubitemid 2136223)
135. Kern ER, Rybak RJ, Hartline CB, et al. Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections. Antivir Chem Chemother 2001;12(Suppl 1):149-56
136. Mocarski ES, Bonyhadi M, Salimi S, et al. Human cytomegalovirus in a SCID-hu mouse: Thymic epithelial cells are prominent targets of viral replication. Proc Natl Acad Sci USA 1993;90(1):104-8 (Pubitemid 23010258)
137. Bravo FJ, Cardin RD, Bernstein DI. A model of human cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res 2007;76(2):104-10 (Pubitemid 47410313)
138. Rawlinson WD, Zeng F, Farrell HE, et al. The murine cytomegalovirus (MCMV) homolog of the HCMV phosphotransferase (UL97(pk)) gene. Virology 1997;233(2):358-63 (Pubitemid 27314821)
139. Wagner M, Michel D, Schaarschmidt P, et al. Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: PM97 does not confer ganciclovir sensitivity. J Virol 2000;74(22):10729-36
140. Prichard MN, Gao N, Jairath S, et al. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 1999;73(7):5663-70 (Pubitemid 29274851)
141. McGregor A, Choi KY, Cui X, et al. Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir. Antiviral Res 2008;78(3):250-9
142. McGregor A. Current and new cytomegalovirus antivirals and novel animal model strategies. Inflamm Allgery Drug Targets 2010;9(4):286-99
143. Johnson KP. Mouse cytomegalovirus: placental infection. J Infect Dis 1969;120(4):445-50
144. Enders AC. A comparative study of the fine structure of the trophoblast in several hemochorial placentas. Am J Anat 1965;116:29-67
145. Tsutsui Y. Developmental disorders of the mouse brain induced by murine cytomegalovirus: animal models for congenital cytomegalovirus infection. Pathol Int 1995;45(2):91-102
146. Cekinovic D, Golemac M, Pugel EP, et al. Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol 2008;82(24):12172-80
147. Mutnal MB, Cheeran MC, Hu S, et al. Murine cytomegalovirus infection of neural stem cells alters neurogenesis in the developing brain. PLoS One 2011;6(1):e16211
148. Tsutsui Y, Kosugi I, Kawasaki H, et al. Roles of neural stem progenitor cells in cytomegalovirus infection of the brain in mouse models. Pathol Int 2008;58(5):257-67 (Pubitemid 351579635)
149. Schachtele SJ, Mutnal MB, Schleiss MR, et al. Cytomegalovirus-induced sensorineural hearing loss with persistent cochlear inflammation in neonatal
150. Luker GD, Bardill JP, Prior JL, et al. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J Virol 2002;76(23):12149-61 (Pubitemid 35304313)
151. Klenovsek K, Weisel F, Schneider A, et al. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 2007;110(9):3472-9 (Pubitemid 350106344)
152. Yamada S, Kosugi I, Katano H, et al. In vivo imaging assay for the convenient evaluation of antiviral compounds against cytomegalovirus in mice. Antiviral Res 2010;88(1):45-52
153. Tsutsui Y, Kawasaki H, Kosugi I. Reactivation of latent cytomegalovirus infection in mouse brain cells detected after transfer to brain slice cultures. J Virol 2002;76(14):7247-54
154. Lagenaur LA, Manning WC, Vieira J, et al. Structure and function of the murine cytomegalovirus sgg1 gene: a determinant of viral growth in salivary gland acinar cells. J Virol 1994;68(12):7717-27 (Pubitemid 24362658)
155. Barry PA, Strelow L. Development of breeding populations of rhesus macaques (macaca mulatta) that are specific pathogen-free for rhesus cytomegalovirus. Comp Med 2008;58(1):43-6 (Pubitemid 351413456)
156. Swanson R, Bergquam E, Wong SW. Characterization of rhesus cytomegalovirus genes associated with anti-viral susceptibility. Virology 1998;240(2):338-48 (Pubitemid 28384240)
157. North TW, Sequar G, Townsend LB, et al. Rhesus cytomegalovirus is similar to human cytomegalovirus in susceptibility to benzimidazole nucleosides. Antimicrob Agents Chemother 2004;48(7):2760-5 (Pubitemid 38823462)
158. Chang WL, Barry PA. Cloning of the full-length rhesus cytomegalovirus genome as an infectious and self-excisable bacterial artificial chromosome for analysis of viral pathogenesis. J Virol 2003;77(9):5073-83 (Pubitemid 36460922)
159. Powers C, Fruh K. Rhesus CMV: an emerging animal model for human CMV. Med Microbiol Immunol 2008;197(2):109-15
160. Yue Y, Barry PA. Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus. Adv Virus Res 2008;72:207-26
161. Padilla-Carlin DJ, McMurray DN, Hickey AJ. The guinea pig as a model of infectious diseases. Comp Med 2008;58(4):324-40
162. Hickey AJ. Guinea pig model of infectious disease - viral infections. Curr Drug Targets 2011;112(7):1018-23
163. Kaufmann P. Guinea pig cavia procellus. In: Benirschke K. editor. Comparitive placentation. Available from: http://medicine.ucsd.edu/cpa/ guinea/htm 2004
164. Kumar ML, Nankervis GA. Experimental congenital infection with cytomegalovirus: a guinea pig model. J Infect Dis 1978;138(5):650-4 (Pubitemid 9058760)
165. Griffith BP, Hsiung GD. Cytomegalovirus infection in guinea pigs. IV. maternal infection at different stages of gestation. J Infect Dis 1980;141(6):787-93 (Pubitemid 10070036)
166. Carter AM. Animal models of human placentation-a review. Placenta 2007;28(Suppl A):S41-7 (Pubitemid 46508694)
167. Mess A. The guinea pig placenta: model of placental growth dynamics. Placenta 2007;28(8-9):812-15 (Pubitemid 47074385)
168. Hartley JW, Rowe WP, Huebner RJ. Serial propagation of the guinea pig salivary gland virus in tissue culture. Proc Soc Exp Biol Med 1957;96(2):281-5
169. Aquino-de Jesus MJ, Griffith BP. Cytomegalovirus infection in immunocompromised guinea pigs: a model for testing antiviral agents in vivo. Antiviral Res 1989;12(4):181-93
170. Woolf NK, Koehrn FJ, Harris JP, et al. Congenital cytomegalovirus labyrinthitis and sensorineural hearing loss in guinea pigs. J Infect Dis 1989;160(6):929-37 (Pubitemid 20002758)
171. Woolf NK. Experimental congenital cytomegalovirus labyrinthitis and sensorineural hearing loss. Am J Otolaryngol 1990;11(5):299-303
172. Woolf NK, Harris JP, Ryan AF, et al. Hearing loss in experimental cytomegalovirus infection of the guinea pig inner ear: prevention by systemic immunity. Ann Otol Rhinol Laryngol 1985;94(4 Pt 1):350-6 (Pubitemid 15007472)
173. White DR, Choo DI, Stroup G, et al. The effect of cidofovir on cytomegalovirus-induced hearing loss in a guinea pig model. Arch Otolaryngol Head Neck Surg 2006;132(6):608-15 (Pubitemid 43927037)
174. Bourne N, Bravo FJ, Bernstein DI. Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals. Antiviral Res 2000;47(2):103-9
175. Bravo FJ, Cardin RD, Bernstein DI. Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2006;193(4):591-7 (Pubitemid 43202751)
176. Schleiss MR, Anderson JL, McGregor A. Cyclic cidofovir (cHPMPC) prevents congenital cytomegalovirus infection in a guinea pig model. Virol J 2006b;3:9
177. Parker S, Touchette E, Oberle C, et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 2008;77(1):39-49
178. Toth K, Spencer JF, Dhar D, et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008;105(20):7293-7 (Pubitemid 351754471)
179. Nixon DE, McVoy MA. Dramatic effects of 2-bromo-5,6-dichloro-1-beta- D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus. J Virol 2004;78(4):1623-35 (Pubitemid 38176695)
180. Williams SL, Hartline CB, Kushner NL, et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 2003;47(7):2186-92 (Pubitemid 36753570)
181. Schleiss MR, Bernstein DI, McVoy MA, et al. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res 2005;65(1):35-43 (Pubitemid 40094772)
182. Weber O, Bender W, Eckenberg P, et al. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res 2001;49(3):179-89 (Pubitemid 32322471)
183. Chatterjee A, Harrison CJ, Britt WJ, et al. Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis 2001;183(11):1547-53 (Pubitemid 32466691)
184. Bratcher DF, Bourne N, Bravo FJ, et al. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 1995;172(4):944-50
185. Britt WJ, Mach M. Human cytomegalovirus glycoproteins. Intervirology 1996;39(5-6):401-12 (Pubitemid 27174142)
186. Gretch DR, Kari B, Gehrz RC, et al. A multigene family encodes the human cytomegalovirus glycoprotein complex gcII (gp47-52 complex). J Virol 1988;62(6):1956-62
187. Huber MT, Compton T. The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol 1998;72(10):8191-7 (Pubitemid 28421815)
188. Britt WJ, Harrison C. Identification of an abundant disulfide-linked complex of glycoproteins in the envelope of guinea pig cytomegalovirus. Virology 1994;201(2):294-302 (Pubitemid 24187274)
189. Schleiss MR, Bourne N, Stroup G, et al. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 2004;189(8):1374-81 (Pubitemid 38543585)
190. Hobom U, Brune W, Messerle M, et al. Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol 2000;74(17):7720-9 (Pubitemid 30641615)
191. Fong CK, Cohen SD, McCormick S, et al. Antiviral effect of 9-(1,3-dihydroxy- 2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model. Antiviral Res 1987;7(1):11-23 (Pubitemid 17192941)
192. Woolf NK, Ochi JW, Silva EJ, et al. Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis. Antimicrob Agents Chemother 1988;32(6):865-72
193. Fox DS, Schleiss MR. Sequence and transcriptional analysis of the guinea pig cytomegalovirus UL97 homolog. Virus Genes 1997;15(3):255-64 (Pubitemid 28037043)
194. Chang MH, Cirillo SL, Cirillo JD. Using luciferase to image bacterial infections in mice. J Vis Exp 2011(48):2547
195. Lischka P, Zimmermann H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr Opin Pharmacol 2008;8(5):541-8
196. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000;13(1):83; 121, table of contents
197. Singh N. Optimization of outcomes related to cytomegalovirus in organ transplant recipients. Transplantation 2006;82(1):15-16 (Pubitemid 44296971)
198. Singh N, Wagener MM. Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2006;144(6):456; 7; author reply 457
199. Michel D and Mertens T. Antiviral intervention, resistance and perspectives. In: Matthias J. Reddhase editor. Cytomegaloviruses [Chapter 27]. Molecular biology and immunology. Caister Academic Press; Wymondham, Norfolk, UK: 2005. p. 573-90